Ipamorelin is a synthetic peptide which is designed to be applied to an animal’s body to release growth hormone. The function of this chemical is very similar to GHRP-6; these two peptides are commonly used in comparison to each other during research programs.
The main difference between these two peptides is that the amino acid chain for ipamorelin is quite short, containing only five amino acids and only has a molecular mass of 711.86 which allows an animal’s body to use it to build muscle while burning fat.
In comparison to these effects, GHRP-6 is a hexapeptide while ipamorelin is a pentapeptide. Given the more concentrated nature of the chemical, smaller applications can be used on animal test subjects to gain similar results to other GHRP based peptides which is convenient for those that are attempting to monitor the effects of these chemicals in different increment levels as there is a much lower risk of the animals developing side effects.
This is also an ideal chemical for research facilities that are attempting to monitor long-term growth effects as it can be administered regularly in much safer conditions than those seen with similar peptides.
Results Associated with Ipamorelin
The administration of ipamorelin to animal test subjects is generally associated with an increase in the production of muscle tissue while creating weight gain that was not fat dependent.
Test subjects that were given consistent administrations of ipamorelin did not show an increase in their levels of IGF-1 which would normally increase appetite and fat production in the body. Bone development also appears to be lacking when ipamorelin is used to stimulate growth in animal tissue.
- The amount of cells in the leg bones of animals did not appear to be effected significantly by the presence of ipamorelin, though the muscle tissues in these areas would continue to see growth. This appears to be a positive effect of using this chemical on animal tissue because it reduces the risk that consistent application of this chemical could cause bone deformities.
- Following aggressive applications of ipamorelin an animal’s pituitary gland will start to reduce plasma hormone levels, a reaction that is not seen when this gland is exposed to similar sized applications of GHRH.
This is also considered to be a positive effect, as it shows that applying ipamorelin for medical purposes will not cause an animal to stop producing natural growth hormones, creating a dependency on the hormone. It also indicates that ipamorelin is a somewhat selective chemical that will only cause the animal to produce certain growth hormones, a condition that merits further study.
Key Differences to Similar Peptides
Ipamorelin was specifically designed to bring about similar reactions to other GHRP based peptides, but there are notable differences that appear to give this peptide more control.
Ipamorelin does not appear to cause hunger when it is applied to an animal. This is a key characteristic of GHRP-6 which is consistently used to help manage symptoms in animal test subjects that are wasting or showing other signs of failing to thrive. GHRP-6 is used to stimulate the presence of insulin growth factors in an animal as well as growth hormone, while ipamorelin does not appear to impact the presence of IGF.
Research has shown that the hormone levels in an animal test subject produced by ipamorelin are comparable to GHRP-6, particularly in animal test subjects that were healthy. Both have been shown to affect the LH, FSH, TSH and PRL levels as well as the blood serum plasma, depending on the nature of the application.
It is theorized that applying ipamorelin to an animal could help researchers increase acetylchlorine or cortisol levels, though this is still being researched. Studies that have been conducted so far indicate that applying ipamorelin alongside GHRP-2 or GHRP-6 increases these effects as ipamorelin does not appear to have a significant impact on these chemical levels in the plasma when it is applied to an animal on its own.
Ipamorelin is also unique in the fact that it does not appear to impact prolactin or cortisol in the body the way that GHRP-2 or GHRP-6 do with consistent applications. Ipamorelin also appears to produce results at a slower delivery level compared to these other chemicals which causes longer production of growth hormone overall.